Stable Semi-Mature Tolerogenic Dendritic Cells for Autoimmune Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for generating tolerogenic dendritic cells (tolDCs) face challenges in maintaining stability and immune tolerance, particularly in autoimmune diseases and graft rejection, as they can switch to an activated phenotype upon encountering proinflammatory signals, potentially exacerbating autoimmune reactions.

Innovation Solution

A method involving the culture of monocytes in a specific sequence of media containing GM-CSF, IL-4, Dexamethasone, vitamin D2, and MPLA, which induces the differentiation and stabilization of semi-mature tolerogenic dendritic cells, maintaining their tolerogenic properties even in inflammatory environments.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional methods are used to generate tolerogenic dendritic cells, then the cells can be produced, but they switch to an activated phenotype upon encountering proinflammatory signals, potentially exacerbating autoimmune reactions

Engineering Contradiction:

Improvestability of tolerogenic phenotypeVSAvoidswitch to activated phenotype in inflammatory environment

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary action by pre-conditioning dendritic cells with dexamethasone and vitamin D2 during in vitro differentiation to establish a stable tolerogenic phenotype before administration. This pre-treatment ensures that the cells are pre-adapted to resist phenotypic switching when encountering proinflammatory signals in vivo, thereby maintaining their tolerogenic function reliably

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent employs parameter changes by modifying the differentiation conditions through specific cytokine combinations (GM-CSF, IL-4, IL-10) and pharmacological agents (dexamethasone, vitamin D2) to generate dendritic cells with altered phenotypic parameters. These parameter changes result in cells with enhanced stability and resistance to activation signals, preventing the harmful phenotypic switching

Inventive Principle:

Principle #35Parameter changes

2Reliability

If dendritic cells are fully matured to enhance antigen presentation, then immune activation is improved, but proinflammatory cytokine production increases, potentially worsening autoimmune responses

Engineering Contradiction:

Improveantigen presentation capabilityVSAvoidproinflammatory cytokine production

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies local quality by creating dendritic cells with differentiated functional properties: they possess enhanced antigen presentation capability through upregulated MHC and costimulatory molecules, while simultaneously maintaining suppressed proinflammatory cytokine production through tolerogenic conditioning. This local quality differentiation allows the cells to perform beneficial immune functions without generating harmful inflammatory responses

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent implements partial action by generating semi-mature dendritic cells that possess intermediate characteristics rather than full maturation. These cells have sufficient antigen presentation capability for therapeutic efficacy but deliberately lack the full proinflammatory cytokine production capacity of completely matured cells, thereby avoiding the harmful effects while maintaining beneficial functions

Inventive Principle:

Principle #16Partial or excessive action

Data Source

PatentEP3209305B1Tolerogenic dendritic cells, methods of producing the same, and uses thereof

Publication Date: 2020.03.18 SOTIO AS

Figure 1A
Figure 1B
Figure 2A

AI summary

Described herein are methods for the preparation of stable semi-mature tolerogenic dendritic cells and compositions comprising such stable semi-mature tolerogenic dendritic cells. The stable semi-mature tolerogenic dendritic cells described herein and compositions thereof can be used for the establishment of immune tolerance when treating an autoimmune disease, graft rejection and/or graft-versus-host disease.